Different fatty acid metabolism effects of (-)-Epigallocatechin-3-Gallate and C75 in Adenocarcinoma lung cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Relat, Joana ^a   Blancafort, Adriana ^b   Oliveras, Glòria ^b   Cufí, Sílvia ^b   Haro, Diego ^a   Marrero, Pedro F ^a   Puig, Teresa ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

Author keywords

C75; EGCG; EGFR; Fatty acid metabolism; Fatty acid synthase; Inhibitors; Lung cancer; Weight loss; Xenograft

Indexed keywords

CPT ENZYME; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; FATTY ACID; FATTY ACID SYNTHASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER MODEL; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

4-BUTYROLACTONE; ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CARNITINE O-PALMITOYLTRANSFERASE; CATECHIN; CELL LINE, TUMOR; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; WEIGHT LOSS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863443673     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-280     Document Type: Article

References (44)

1. Smith S. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. FASEB J 1994, 8(15):1248-1259.
2. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16(3):202-208. 10.1016/S0899-9007(99)00266-X, 10705076.
3. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006, 66(12):5977-5980. 10.1158/0008-5472.CAN-05-4673, 16778164.
4. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7(10):763-777. 10.1038/nrc2222, 17882277.
5. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997, 3(11):2115-2120.
6. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002, 98(1):19-22. 10.1002/ijc.10127, 11857379.
7. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger DC, Grizzle WE. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000, 31(9):1068-1073. 10.1053/hupa.2000.9842, 11014573.
8. Relat J, Puig T. Design of Anti-Fasn Molecules as a New Anti-Tumour Modality. Frontiers in Drug Design & Discovery 2010, Publishers BS.
9. Visca P, Sebastiani V, Botti C, Diodoro MG, Lasagni RP, Romagnoli F, Brenna A, De Joannon BC, Donnorso RP, Lombardi G, et al. Fatty acid synthase (FAS) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res 2004, 24(6):4169-4173.
10. Puig T, Turrado C, Benhamú B, Aguilar H, Relat J, Ortega-Gutiérrez S, Casals G, Marrero PF, Urruticoechea A, Haro D, et al. Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. Clin Cancer Res 2009, 15(24):7608-7615. 10.1158/1078-0432.CCR-09-0856, 20008854.
11. Puig T, Vázquez-Martín A, Relat J, Pétriz J, Menéndez JA, Porta R, Casals G, Marrero PF, Haro D, Brunet J, et al. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Canc Res Treat 2008, 109(3):471-479.
12. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 2002, 62(3):642-646.
13. Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 2004, 24(3):591-608.
14. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, Park BW, Kim KS. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 2007, 282(36):26122-26131. 10.1074/jbc.M702854200, 17631500.
15. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 2008, 41(1):59-85. 10.1111/j.1365-2184.2007.00498.x, 18211286.
16. Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun 2009, 385(3):454-459. 10.1016/j.bbrc.2009.05.085, 19467222.
17. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006, 18(6):598-608. 10.1016/j.ceb.2006.10.005, 17046224.
18. Kim K, Kim HY, Cho HK, Kim KH, Cheong J. The SDF-1alpha/CXCR4 axis induces the expression of fatty acid synthase via sterol regulatory element-binding protein-1 activation in cancer cells. Carcinogenesis 2010, 31(4):679-686. 10.1093/carcin/bgp329, 20067991.
19. Vance D, Goldberg I, Mitsuhashi O, Bloch K. Inhibition of fatty acid synthetases by the antibiotic cerulenin. Biochem Biophys Res Commun 1972, 48(3):649-656. 10.1016/0006-291X(72)90397-X, 4625866.
20. Zhao W, Kridel S, Thorburn A, Kooshki M, Little J, Hebbar S, Robbins M. Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer 2006, 95(7):869-878. 10.1038/sj.bjc.6603350, 2360524, 16969344.
21. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 2000, 97(7):3450-3454. 10.1073/pnas.97.7.3450, 16260, 10716717.
22. Vergote D, Cren-Olivé C, Chopin V, Toillon RA, Rolando C, Hondermarck H, Le Bourhis X. (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts. Breast Canc Res Treat 2002, 76(3):195-201.
23. Wang X, Tian W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun 2001, 288(5):1200-1206. 10.1006/bbrc.2001.5923, 11700039.
24. Brusselmans K, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 2003, 106(6):856-862. 10.1002/ijc.11317, 12918062.
25. Nicot C, Napal L, Relat J, González S, Llebaria A, Woldegiorgis G, Marrero PF, Haro D. C75 activates malonyl-CoA sensitive and insensitive components of the CPT system. Biochem Biophys Res Commun 2004, 325(3):660-664. 10.1016/j.bbrc.2004.10.085, 15541339.
26. Puig T, Relat J, Marrero PF, Haro D, Brunet J, Colomer R. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Res 2008, 28(6A):3671-3676.
27. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
28. Lee JS, Orita H, Gabrielson K, Alvey S, Hagemann RL, Kuhajda FP, Gabrielson E, Pomper MG. FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer. Pharm Res 2007, 24(6):1202-1207. 10.1007/s11095-007-9264-x, 17404812.
29. Shim JH, Su ZY, Chae JI, Kim DJ, Zhu F, Ma WY, Bode AM, Yang CS, Dong Z. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Canc Prev Res Phila 2010, 3(5):670-679.
30. Li GX, Chen YK, Hou Z, Xiao H, Jin H, Lu G, Lee MJ, Liu B, Guan F, Yang Z, et al. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis 2010, 31(5):902-910. 10.1093/carcin/bgq039, 2864413, 20159951.
31. Yamauchi R, Sasaki K, Yoshida K. Identification of epigallocatechin-3-gallate in green tea polyphenols as a potent inducer of p53-dependent apoptosis in the human lung cancer cell line A549. Toxicol Vitro 2009, 23(5):834-839.
32. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003, 63(1):132-139.
33. Menendez JA, Lupu R. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz) 2004, 52(6):414-426.
34. Menendez JA, Lupu R, Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 2005, 18(6):375-385. 10.1358/dnp.2005.18.6.927929, 16247515.
35. Jin Q, Yuan LX, Boulbes D, Baek JM, Wang YN, Gomez-Cabello D, Hawke DH, Yeung SC, Lee MH, Hortobagyi GN, et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Canc Res 2010, 12(6):R96.
36. Liang YC, Lin-shiau SY, Chen CF, Lin JK. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997, 67(1):55-65. 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V, 9328839.
37. Shimizu M, Deguchi A, Joe AK, Mckoy JF, Moriwaki H, Weinstein IB. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 2005, 5(1):69-78.
38. Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, Weinstein IB. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005, 11(7):2735-2746. 10.1158/1078-0432.CCR-04-2014, 15814656.
39. Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, Mohr S, Yang CS. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Canc Epidemiol Biomarkers Prev 2002, 11(10 Pt 1):1025-1032.
40. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006, 94(2):195-199. 10.1038/sj.bjc.6602902, 2361102, 16404421.
41. Lin VC, Chou CH, Lin YC, Lin JN, Yu CC, Tang CH, Lin HY, Way TD. Osthole suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt/mTOR pathway. J Agric Food Chem 2010, 58(8):4786-4793. 10.1021/jf100352c, 20218616.
42. Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY, Way TD. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol Nutr Food Res 2009, 53(9):1156-1165. 10.1002/mnfr.200800592, 19662644.
43. Jackowski S, Wang J, Baburina I. Activity of the phosphatidylcholine biosynthetic pathway modulates the distribution of fatty acids into glycerolipids in proliferating cells. Biochim Biophys Acta 2000, 1483(3):301-315. 10.1016/S1388-1981(99)00203-6, 10666565.
44. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A 2002, 99(14):9498-9502. 123169, 12060712.